Goldman Sachs’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.43M | Buy |
3,229,887
+2,241,420
| +227% | +$3.26M | ﹤0.01% | 3814 |
|
|
2026
Q1 | $1.3M | Sell |
988,467
-390,405
| -28% | -$698K | ﹤0.01% | 4896 |
|
|
2025
Q4 | $2.58M | Buy |
1,378,872
+869,445
| +171% | +$1.67M | ﹤0.01% | 4351 |
|
|
2025
Q3 | $652K | Buy |
509,427
+24,686
| +5% | +$33.4K | ﹤0.01% | 5336 |
|
|
2025
Q2 | $601K | Sell |
484,741
-1,379,742
| -74% | -$1.59M | ﹤0.01% | 5054 |
|
|
2025
Q1 | $2.2M | Sell |
1,864,483
-2,928,293
| -61% | -$4.49M | ﹤0.01% | 4080 |
|
|
2024
Q4 | $8.77M | Buy |
4,792,776
+554,509
| +13% | +$1.08M | ﹤0.01% | 2923 |
|
|
2024
Q3 | $7.21M | Buy |
4,238,267
+255,702
| +6% | +$420K | ﹤0.01% | 3022 |
|
|
2024
Q2 | $5.46M | Buy |
3,982,565
+1,776,559
| +81% | +$3.59M | ﹤0.01% | 3066 |
|
|
2024
Q1 | $8.27M | Buy |
2,206,006
+614,899
| +39% | +$3.6M | ﹤0.01% | 2648 |
|
|
2023
Q4 | $15.6M | Sell |
1,591,107
-102,286
| -6% | -$837K | ﹤0.01% | 2131 |
|
|
2023
Q3 | $14.1M | Sell |
1,693,393
-768,448
| -31% | -$8.78M | ﹤0.01% | 2084 |
|
|
2023
Q2 | $32.7M | Buy |
2,461,841
+142,549
| +6% | +$1.73M | 0.01% | 1422 |
|
|
2023
Q1 | $26.9M | Sell |
2,319,292
-220,869
| -9% | -$2.2M | 0.01% | 1555 |
|
|
2022
Q4 | $20.8M | Sell |
2,540,161
-1,115,284
| -31% | -$9.61M | 0.01% | 1917 |
|
|
2022
Q3 | $21.2M | Sell |
3,655,445
-4,783,127
| -57% | -$27.4M | 0.01% | 1808 |
|
|
2022
Q2 | $37.3M | Buy |
8,438,572
+5,533,953
| +191% | +$33.6M | 0.01% | 1349 |
|
|
2022
Q1 | $26.4M | Buy |
2,904,619
+228,964
| +9% | +$2.64M | 0.01% | 1823 |
|
|
2021
Q4 | $54.7M | Buy |
2,675,655
+309,978
| +13% | +$7.48M | 0.01% | 1263 |
|
|
2021
Q3 | $60.4M | Sell |
2,365,677
-263,165
| -10% | -$7.8M | 0.01% | 1128 |
|
|
2021
Q2 | $91.9M | Buy |
2,628,842
+1,410,554
| +116% | +$41M | 0.02% | 785 |
|
|
2021
Q1 | $40.6M | Buy |
1,218,288
+948,644
| +352% | +$33.2M | 0.01% | 1338 |
|
|
2020
Q4 | $7M | Sell |
269,644
-146,619
| -35% | -$2.49M | ﹤0.01% | 2738 |
|
|
2020
Q3 | $4.11M | Sell |
416,263
-501,978
| -55% | -$2.89M | ﹤0.01% | 3052 |
|
|
2020
Q2 | $3.17M | Sell |
918,241
-1,696,594
| -65% | -$5.78M | ﹤0.01% | 3128 |
|
|
2020
Q1 | $8M | Sell |
2,614,835
-587,288
| -18% | -$2.4M | ﹤0.01% | 2250 |
|
|
2019
Q4 | $16.5M | Sell |
3,202,123
-19,827
| -0.6% | -$101K | ﹤0.01% | 2029 |
|
|
2019
Q3 | $16.6M | Sell |
3,221,950
-2,075,410
| -39% | -$11.6M | ﹤0.01% | 1929 |
|
|
2019
Q2 | $32M | Buy |
5,297,360
+2,437,877
| +85% | +$17.1M | 0.01% | 1484 |
|
|
2019
Q1 | $20.7M | Buy |
2,859,483
+204,228
| +8% | +$1.48M | 0.01% | 1839 |
|
|
2018
Q4 | $19.6M | Buy |
2,655,255
+2,435,703
| +1,109% | +$15.4M | 0.01% | 1821 |
|
|
2018
Q3 | $1.19M | Buy |
219,552
+60,234
| +38% | +$258K | ﹤0.01% | 3941 |
|
|
2018
Q2 | $566K | Sell |
159,318
-79,482
| -33% | -$220K | ﹤0.01% | 4437 |
|
|
2018
Q1 | $490K | Buy |
238,800
+86,393
| +57% | +$224K | ﹤0.01% | 4504 |
|
|
2017
Q4 | $402K | Buy |
152,407
+13,431
| +10% | +$47K | ﹤0.01% | 4994 |
|
|
2017
Q3 | $729K | Sell |
138,976
-11,079
| -7% | -$47.6K | ﹤0.01% | 4833 |
|
|
2017
Q2 | $534K | Buy |
150,055
+29,192
| +24% | +$118K | ﹤0.01% | 5044 |
|
|
2017
Q1 | $625K | Sell |
120,863
-120,046
| -50% | -$588K | ﹤0.01% | 4815 |
|
|
2016
Q4 | $915K | Buy |
240,909
+56,524
| +31% | +$411K | ﹤0.01% | 4531 |
|
|
2016
Q3 | $1.65M | Buy |
184,385
+109,493
| +146% | +$915K | ﹤0.01% | 3989 |
|
|
2016
Q2 | $527K | Buy |
74,892
+6,605
| +10% | +$60.3K | ﹤0.01% | 4808 |
|
|
2016
Q1 | $580K | Sell |
68,287
-111,469
| -62% | -$1.1M | ﹤0.01% | 4599 |
|
|
2015
Q4 | $2.36M | Buy |
179,756
+120,600
| +204% | +$1.08M | ﹤0.01% | 3481 |
|
|
2015
Q3 | $217K | Sell |
59,156
-26,429
| -31% | -$129K | ﹤0.01% | 5937 |
|
|
2015
Q2 | $493K | Buy |
85,585
+13,864
| +19% | +$80.2K | ﹤0.01% | 5231 |
|
|
2015
Q1 | $419K | Buy |
71,721
+26,091
| +57% | +$180K | ﹤0.01% | 5318 |
|
|
2014
Q4 | $358K | Sell |
45,630
-337,883
| -88% | -$2.16M | ﹤0.01% | 5605 |
|
|
2014
Q3 | $1.88M | Buy |
383,513
+321,202
| +515% | +$1.68M | ﹤0.01% | 3995 |
|
|
2014
Q2 | $385K | Buy |
62,311
+31,649
| +103% | +$158K | ﹤0.01% | 5557 |
|
|
2014
Q1 | $164K | Buy |
30,662
+18,483
| +152% | +$117K | ﹤0.01% | 6199 |
|
|
2013
Q4 | $64K | Buy |
12,179
+1,207
| +11% | +$5.54K | ﹤0.01% | 6379 |
|
|
2013
Q3 | $61K | Buy |
+10,972
| New | +$38.1K | ﹤0.01% | 6270 |
|
Other funds holding PACB
AIM
NAMA
Goldman Sachs's PACB Position: Q2 2026 in Review
Goldman Sachs increased its Pacific Biosciences (PACB) stake by 227% in Q2 2026, buying an estimated $3.26M and bringing the position to 3,229,887 shares worth $5.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3814.
Goldman Sachs first reported a position in PACB in Q3 2013 and has held it in 52 quarters since. The position peaked at $91.9M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Goldman Sachs held 3,229,887 shares of Pacific Biosciences worth $5.43M as of Q2 2026.
- Goldman Sachs bought 2,241,420 Pacific Biosciences shares in Q2 2026, an estimated $3.26M.
- Pacific Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3814 holding.
- Goldman Sachs first reported a position in Pacific Biosciences in Q3 2013 and has held it in 52 quarters since.
- Goldman Sachs's Pacific Biosciences position peaked at $91.9M in Q2 2021.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.